Marksans Pharma Limited has informed the Exchange regarding a press release dated September 23, 2025, titled "Marksans Pharma Ltd's subsidiary Relonchem Limited in UK received marketing authorisation for its products from UK MHRA.".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK MHRA (Medicines and Healthcare products Regulatory Agency) for two strengths of Moxonidine Tablets — 200 microgram and 400 microgram. Moxonidine is used in the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic segment. Relonchem is a fully-owned UK subsidiary of Marksans Pharma, and the parent company already operates manufacturing facilities approved by USFDA, UKMHRA, and Australian TGA. This approval enables Relonchem to commercially market these products in the UK regulated market, adding to the company's growing product portfolio across global markets.
Positive for the company — the UK MHRA approval for two Moxonidine strengths strengthens Marksans Pharma's product offerings in the regulated UK market and supports potential revenue growth in the cardiovascular segment through its subsidiary channel.